{"transactions":[{"id":3500536,"issuer":{"id":7501,"kind":"organization","name":"Harvard Apparatus Regenerative Technology, Inc.","symbol":"HRGN"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-05T16:32:10.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":8411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Stock Option was granted in lieu of 2019 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2019, September 30, 2019, and December 31, 2019."}],"balance_after":18775,"derivative":{"exercise_price":2.9,"expiration_date":"2029-06-03","underlying":"Common Stock, par value $0.01 per share","underlying_shares":8411},"source":{"system":"sec-edgar","filing":"0001144204-19-029895","document":"tv523168_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000114420419029895/tv523168_form4.xml","form_type":"4"}},{"id":3500535,"issuer":{"id":7501,"kind":"organization","name":"Harvard Apparatus Regenerative Technology, Inc.","symbol":"HRGN"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-05T16:32:10.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 3, 2019, December 3, 2019, March 3, 2020, and June 3, 2020."}],"balance_after":10364,"derivative":{"exercise_price":2.9,"expiration_date":"2029-06-03","underlying":"Common Stock, par value $0.01 per share","underlying_shares":10364},"source":{"system":"sec-edgar","filing":"0001144204-19-029895","document":"tv523168_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000114420419029895/tv523168_form4.xml","form_type":"4"}},{"id":3668138,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T16:31:22.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":450750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company."}],"balance_after":450750,"derivative":{"exercise_price":0.62,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":450750},"source":{"system":"sec-edgar","filing":"0000899243-19-003035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000089924319003035/doc4.xml","form_type":"4"}},{"id":3763242,"issuer":{"id":7501,"kind":"organization","name":"Harvard Apparatus Regenerative Technology, Inc.","symbol":"HRGN"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-11-15T19:06:48.000Z","date":"2018-11-13","kind":"grant","acquired":true,"shares":10897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option shares will vest in four equal installments on February 13, 2019, May 13, 2019, August 13, 2019, and November 13, 2019."}],"balance_after":10897,"derivative":{"exercise_price":2.75,"expiration_date":"2028-11-13","underlying":"Common Stock, par value $0.01 per share","underlying_shares":10897},"source":{"system":"sec-edgar","filing":"0001144204-18-060325","document":"tv507434_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000114420418060325/tv507434_form4.xml","form_type":"4"}},{"id":4079242,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-02T19:57:21.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 1, 2018, through February 1, 2022, subject to the Reporting Person's continued service to the Company."}],"balance_after":250000,"derivative":{"exercise_price":3.08,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-002740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000089924318002740/doc4.xml","form_type":"4"}},{"id":4264516,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-07-05T16:30:31.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on June 1, 2018, and the remainder of this option shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Company."}],"balance_after":500000,"derivative":{"exercise_price":2.22,"expiration_date":"2027-07-03","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-17-017790","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000089924317017790/doc4.xml","form_type":"4"}},{"id":4414185,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-01T12:12:23.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":37500,"price":39.75,"value":1490625.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.75,"expiration_date":"2026-03-04","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000911916-17-000068","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191617000068/edgar.xml","form_type":"4"}},{"id":4414184,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-01T12:12:23.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":38.94,"value":1168200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options, which provided that 25% of the shares vested on August 4, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":7.56,"expiration_date":"2025-08-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000911916-17-000068","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191617000068/edgar.xml","form_type":"4"}},{"id":4414183,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-01T12:12:23.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":180254,"price":36.5,"value":6579271.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options, which provided that 25% of the shares vested on May 5, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2025-05-05","underlying":"Common Stock","underlying_shares":180254},"source":{"system":"sec-edgar","filing":"0000911916-17-000068","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191617000068/edgar.xml","form_type":"4"}},{"id":4414182,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-01T12:12:23.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":37500,"price":46.5,"value":1743750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units, which by their terms were convertible into common stock of the Issuer on a one-for-one basis, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000911916-17-000068","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191617000068/edgar.xml","form_type":"4"}},{"id":4414181,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-01T12:12:23.000Z","date":"2017-03-01","kind":"other","acquired":false,"shares":2708,"price":46.5,"value":125922.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 80 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000911916-17-000068","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191617000068/edgar.xml","form_type":"4"}},{"id":4502985,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-01-04T16:24:22.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":1473,"price":36.25,"value":53396.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan."}],"balance_after":40128,"source":{"system":"sec-edgar","filing":"0000911916-17-000026","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191617000026/edgar.xml","form_type":"4"}},{"id":4537182,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":156952,"kind":"person","name":"Dallas Matthew D","position":1,"cik":"0001612396","reported_name":"Dallas Matthew D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-12-01T16:43:56.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":1473,"price":35.1671,"value":51801.1383,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016."}],"balance_after":41601,"source":{"system":"sec-edgar","filing":"0000911916-16-000693","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612396/000091191616000693/edgar.xml","form_type":"4"}}]}